Targets › EPOR
13 programs from 12 companies in 24 trials: 11 Phase 3, 5 Phase 2, 5 Phase 4, 3 Phase 1; Hematology, Genitourinary, Other; next expected readout Dec 2026.
Receptor for erythropoietin, which mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2/STAT5 signaling cascade (By similarity). (UniProt, P19235)
Open in Phaseline: the race on EPOR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Dalian Medical University | Pegmolesatide Continuous erythropoietin receptor activator (CERA) | EPOR | Phase 4 | Renal Anemia in Non-dialysis Chronic Kidney Disease | Dec 2026 |
| Copenhagen University Hospital, Rigshospitalet | Darbepoetin alfa Erythropoietin receptor agonist | EPOR | Phase 4 | Infective Endocarditis (IE) | Apr 2028 |
| Gangnam Severance Hospital | darbepoetin alfa Erythropoietin receptor agonist | EPOR | Phase 4 | Chronic Kidney Disease | – |
| Fundacion Clinic per a la Recerca Biomédica | Darbepoetin Alfa Erythropoietin receptor agonist | EPOR | Phase 3 | Liver Transplant; Complications | Dec 2026 |
| Genexine | Efepoetin Alfa Erythropoietin receptor agonist | EPOR | Phase 3 | Anemia of Chronic Kidney Disease | Jun 2027 |
| Biocad | BCD-131 (pegdarbepoetin beta) Erythropoietin receptor (EPOR) agonist; pegylated darbepoetin beta | EPOR | Phase 3 | Anemia | Oct 2027 |
| Takeda | Elritercept Erythropoietin receptor agonist | EPOR | Phase 3 | Myelodysplastic Syndromes; Myelodysplastic Syndrome; Myelofibrosis | Feb 2028 |
| Incepta Pharmaceuticals | Epoetin Alfa Erythropoietin receptor agonist | EPOR | Phase 3 | Healthy; Hypobaric Hypoxia; Anemia; Encephalopathy … | – |
| University of Washington | Darbepoetin Alfa Erythropoietin receptor agonist | EPOR | Phase 2 | Prematurity | Jan 2027 |
| Takeda | TAK-226 Erythropoietin receptor agonist | EPOR | Phase 2 | Myelodysplastic Syndromes | Jun 2028 |
| Yale University | Darbepoetin alfa Erythropoietin receptor agonist | EPOR | Phase 2 | MDS (Myelodysplastic Syndrome) | Aug 2030 |
| Johns Hopkins University | Erythropoietin (EPO) Erythropoietin receptor agonist; promotes neuroprotection and neuro-repair | EPOR | Phase 1 | Intraventricular Hemorrhage of Prematurity | Sep 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Darbepoetin Alfa Erythropoietin receptor agonist | EPOR | Phase 1 | Myelodysplastic Syndromes | – |
Myelodysplastic Syndromes (5) Anemia (3) Myelofibrosis (2) Anemia of Chronic Kidney Disease (1) Prematurity (1) Renal Anemia in Non-dialysis Chronic Kidney Disease (1) Myelodysplastic Syndrome (1) Chronic Kidney Disease (1) Intraventricular Hemorrhage of Prematurity (1) Liver Transplant; Complications (1) MDS (Myelodysplastic Syndrome) (1) Infective Endocarditis (IE) (1)
protein or peptide (6), mixed (3), antibody (2), small molecule (1)
Takeda (2) Genexine (1) University of Washington (1) The First Affiliated Hospital of Dalian Medical University (1) Gangnam Severance Hospital (1) Johns Hopkins University (1) Biocad (1) Fundacion Clinic per a la Recerca Biomédica (1) H. Lee Moffitt Cancer Center and Research Institute (1) Yale University (1) Copenhagen University Hospital, Rigshospitalet (1) Incepta Pharmaceuticals (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.